FDA
-
-
-
-
-
-
-
Quantum BioPharma gets FDA clearance for Lucid-MS phase 2 MS trial
-
-
-
-
-
-
-
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
-
-
-
-
-
-
-
Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio
-
-
-
-
-
-
-
Quantum BioPharma signs manufacturing agreement for oral MS drug formulation
-
-
-
-
-
-
-
Quantum BioPharma (QNTM) Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND
-
-
-
-
-
-
-
Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales
-
-
-
-
330,652 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

